An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Two companies, Vivani and Novo Nordisk, announced they will work together to test a long-lasting implant that slowly releases semaglutide, the drug you’ve probably heard of in brand names like Ozempic and Wegovy. The goal is to see if an implanted device can deliver the medicine over a long period instead of people taking regular injections or pills. Semaglutide is a man-made version of a natural hormone that helps control appetite and blood sugar. In simple terms, it tells your brain you’re less hungry and it slows how quickly your stomach empties. That’s why it’s used for treating type 2 diabetes and for weight loss under medical supervision. Right now people usually take it as a weekly injection or, in some cases, as a daily pill. This announcement is about testing a delivery method, not a new drug. From the short news line, the companies plan to evaluate whether an implant can provide steady, long-term dosing of semaglutide. The statement doesn’t give study size, patient numbers, or results yet — it’s about starting a development and evaluation program. So there’s no evidence yet that the implant works better or is safer than current options; it’s an early-stage business and technical collaboration. Why this could matter is practical: many people struggle with regular injections, missed doses, or the hassle of ongoing treatment. An implant that reliably releases semaglutide for months could make treatment easier and more consistent, which might improve outcomes for people with diabetes or those using the drug for weight management. It could also change how doctors prescribe and monitor therapy if it reduces the need for frequent clinic visits. There are important caveats. Implants carry their own risks: insertion and removal procedures, infections, device failures, and difficulties adjusting dose quickly if side effects occur. Long-term safety of continuous semaglutide exposure from an implant isn’t known yet. Regulatory approval would be required, and that process needs clinical trial data showing the implant is safe and effective. Finally, the announcement describes a partnership to evaluate the idea — it does not mean an approved product is imminent. Bottom line: Companies are exploring a semaglutide implant to simplify long-term dosing, but we don’t yet have trial results or safety data — it’s an early development step, not a ready-to-use option.
Source: Drug Delivery Business